Protective effects of β1/2 adrenergic receptor deletion in a model of oxygen-induced retinopathy

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 1, 2015, Pages 59-73

  Dal Monte, Massimo ^a   Cammalleri, Maurizio ^a   Mattei, Elisabetta ^b,c   Filippi, Luca ^d   Bagnoli, Paola ^a  

^a UNIVERSITY OF PISA   (Italy)

^b CNR   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Immunoblotting; Immunohistochemistry; Norepinephrine; VEGF

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; BETA ADRENERGIC RECEPTOR; OXYGEN; RNA; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; GENETIC TRANSCRIPTION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OXYGEN-INDUCED RETINOPATHY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETINA NEOVASCULARIZATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DISEASE MODEL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; TOXICITY;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT; OXYGEN; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ADRENERGIC, BETA; RETINAL NEOVASCULARIZATION; RNA; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84920540314     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-15263     Document Type: Article

References (70)

1. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10:133–140.
2. Stahl A, Connor KM, Sapieha P, et al. The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci. 2010;51: 2813–2826.
3. Jarajapu YP, Cai J, Yan Y, et al. Protection of blood retinal barrier and systemic vasculature by insulin-like growth factor binding protein-3. PLoS One. 2012;7:e39398.
4. Tian XF, Xia XB, Xu HZ, Xiong SQ, Jiang J. Caveolin-1 expression regulates blood-retinal barrier permeability and retinal neovascularization in oxygen-induced retinopathy. Clin Exp Ophthalmol. 2012;40:e58–e66.
5. Ristori C, Filippi L, Dal Monte M, et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci. 2011;52:155–170.
6. Berkowitz BA, Roberts R. Evidence for a critical role of panretinal pathophysiology in experimental ROP. Doc Ophthalmol. 2010;120:13–24.
7. Scott A, Fruttiger M. Oxygen-induced retinopathy: a model for vascular pathology in the retina. Eye (Lond). 2010;24:416–421.
8. Bartoli M, Al-Shabrawey M, Labazi M, et al. HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2009;50:4934–4940.
9. Stahl A, Chen J, Sapieha P, et al. Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy. Am J Pathol. 2010;177:2715–2723.
10. Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013;34:19–48.
11. Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res. 2010;29:500–519.
12. North PE, Anthony DC, Young TL, Waner M, Brown HH, Brodsky MC. Retinal neovascular markers in retinopathy of prematurity: aetiological implications. Br J Ophthalmol. 2003; 87:275–278.
13. Aguilar E, Dorrell MI, Friedlander D, et al. Chapter 6. Ocular models of angiogenesis. Methods Enzymol. 2008;444:115–58.
14. Casini G, Dal Monte M, Fornaciari I, Filippi L, Bagnoli P. The badrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases. Prog Retin Eye Res. 2014;42:103–129.
15. Martini D, Dal Monte M, Ristori C, et al. Antiangiogenic effects of b(2)-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem. 2011;119:1317–1329.
16. Walker RJ, Steinle JJ. Role of beta-adrenergic receptors in inflammatory marker expression in M¨uller cells. Invest Ophthalmol Vis Sci. 2007;48:5276–5281.
17. Bai Y, Ma JX, Guo J, et al. Müller cell-derived VEGF is a significant contributor to retinal neovascularization. J Pathol. 2009;219:446–454.
18. Dal Monte M, Martini D, Latina V, Pavan B, Filippi L, Bagnoli P. Beta-adrenoreceptor agonism influences retinal responses to hypoxia in a model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2012;53:2181–2192.
19. Dal Monte M, Casini G, la Marca G, Isacchi B, Filippi L, Bagnoli P. Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Exp Eye Res. 2013; 111:27–35.
20. Filippi L, Cavallaro G, Bagnoli P, et al. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. J Pediatr. 2013;163:1570–1577.e6.
21. Chen J, Joyal JS, Hatton CJ, et al. Propranolol inhibition of badrenergic receptor does not suppress pathological neovascularization in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2012;53:2968–2977.
22. Dal Monte M, Filippi L, Bagnoli P. Beta3-adrenergic receptors modulate vascular endothelial growth factor release in response to hypoxia through the nitric oxide pathway in mouse retinal explants. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:269–278.
23. Shan T, Ma J, Ma Q, et al. b2-AR-HIF-1a: a novel regulatory axis for stress-induced pancreatic tumor growth and angiogenesis. Curr Mol Med. 2013;13:1023–1034.
24. Jiang Y, Zhang Q, Liu L, Tang J, Kern TS, Steinle JJ. b2- adrenergic receptor knockout mice exhibit A diabetic retinopathy phenotype. PLoS One. 2013;8:e70555.
25. Panjala SR, Jiang Y, Kern TS, Thomas SA, Steinle JJ. Increased tumor necrosis factor-a, cleaved caspase 3 levels and insulin receptor substrate-1 phosphorylation in the b1-adrenergic receptor knockout mouse. Mol Vis. 2011;17:1822–1828.
26. Steinle JJ, Kern TS, Thomas SA, McFadyen-Ketchum LS, Smith CP. Increased basement membrane thickness, pericyte ghosts, and loss of retinal thickness and cells in dopamine beta hydroxylase knockout mice. Exp Eye Res. 2009;88:1014–1019.
27. Wiley LA, Berkowitz BA, Steinle JJ. Superior cervical ganglionectomy induces changes in growth factor expression in the rat retina. Invest Ophthalmol Vis Sci. 2006;47:439–443.
28. Wiley LA, Rupp GR, Steinle JJ. Sympathetic innervation regulates basement membrane thickening and pericyte number in rat retina. Invest Ophthalmol Vis Sci. 2005;46: 744–748.
29. Jiang Y, Steinle JJ. Systemic propranolol reduces b-wave amplitude in the ERG and increases IGF-1 receptor phosphorylation in rat retina. Invest Ophthalmol Vis Sci. 2010;51:2730–2735.
30. Panjala SR, Steinle JJ. Insulin and b-adrenergic receptors inhibit retinal endothelial cell apoptosis through independent pathways. Neurochem Res. 2011;36:604–612.
31. Zhang Q, Guy K, Pagadala J, et al. Compound 49b prevents diabetes-induced apoptosis through increased IGFBP-3 levels. Invest Ophthalmol Vis Sci. 2012;53:3004–3013.
32. Jiang Y, Walker RJ, Kern TS, Steinle JJ. Application of isoproterenol inhibits diabetic-like changes in the rat retina. Exp Eye Res. 2010;91:171–179.
33. Chen J, Hellstrom A, Smith LE. Author response: different efficacy of propranolol in mice with oxygen-induced retinopathy: could differential effects of propranolol be related to differences in mouse strains? Invest Ophthalmol Vis Sci. 2012; 53:7728–7729.
34. Filippi L, Dal Monte M, Bagnoli P. Different efficacy of propranolol in mice with oxygen-induced retinopathy: could differential effects of propranolol be related to differences in mouse strains? Invest Ophthalmol Vis Sci. 2012;53:7421–7423.
35. Rohrer DK. Physiological consequences of beta-adrenergic receptor disruption. J Mol Med (Berl). 1998;76:764–772.
36. Vrydag W, Michel MC. Tools to study beta3-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 2007;374:385–398.
37. Patrizio M, Musumeci M, Piccone A, Raggi C, Mattei E, Marano G. Hormonal regulation of b-myosin heavy chain expression in the mouse left ventricle. J Endocrinol. 2013;216:287–296.
38. Ecker PM, Lin CC, Powers J, Kobilka BK, Dubin AM, Bernstein D. Effect of targeted deletions of beta1- and beta2-adrenergicreceptor subtypes on heart rate variability. Am J Physiol Heart Circ Physiol. 2006;290:H192–H199.
39. Bernstein D, Fajardo G, Zhao M, et al. Differential cardioprotective/ cardiotoxic effects mediated by beta-adrenergic receptor subtypes. Am J Physiol Heart Circ Physiol. 2005;289: H2441–H2449.
40. Rohrer DK, Chruscinski A, Schauble EH, Bernstein D, Kobilka BK. Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. J Biol Chem. 1999;274:16701–16708.
41. Patrizio M, Musumeci M, Stati T, et al. Propranolol promotes Egr1 gene expression in cardiomyocytes via beta-adrenoceptors. Eur J Pharmacol. 2008;587:85–89.
42. Patrizio M, Vago V, Musumeci M, et al. cAMP-mediated betaadrenergic signaling negatively regulates Gq-coupled receptormediated fetal gene response in cardiomyocytes. J Mol Cell Cardiol. 2008;45:761–769.
43. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human beta-adrenergic receptor subtypes–characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004; 369:151–159.
44. Blin N, Nahmias C, Drumare MF, Strosberg AD. Mediation of most atypical effects by species homologues of the beta 3- adrenoceptor. Br J Pharmacol. 1994;112:911–919.
45. Liggett SB. Functional properties of the rat and human beta 3- adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells. Mol Pharmacol. 1992;42:634–637.
46. Fu L, Isobe K, Zeng Q, Suzukawa K, Takekoshi K, Kawakami Y. b-adrenoceptor agonists downregulate adiponectin, but upregulate adiponectin receptor 2 and tumor necrosis factor-alpha expression in adipocytes. Eur J Pharmacol. 2007;569:155–162.
47. Delporte ML, Funahashi T, Takahashi M, Matsuzawa Y, Brichard SM. Pre- and post-translational negative effect of betaadrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem J. 2002;367:677–685.
48. Arranz L, Sánchez-Aguilera A, Martín-Pérez D, et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014;512:78–81.
49. Wang X, Seed BA. PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res. 2003;31:e154.
50. Pattyn F, Speleman F, De Paepe A, Vandesompele J. RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res. 2003;31:122–123.
51. Mazumder B, Sampath P, Seshadri V, Maitra RK, DiCorleto PE, Fox PL. Regulated release of L13a from the 60S ribosomal subunit as a mechanism of transcript-specific translational control. Cell. 2003;115:187–198.
52. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25:402–408.
53. Berkowitz BA, Roberts R, Luan H, Peysakhov J, Mao X, Thomas KA. Dynamic contrast-enhanced MRI measurements of passive permeability through blood retinal barrier in diabetic rats. Invest Ophthalmol Vis Sci. 2004;45:2391–2398.
54. Trichonas G, Manola A, Morizane Y, et al. A novel nonradioactive method to evaluate vascular barrier breakdown and leakage. Invest Ophthalmol Vis Sci. 2010;51:1677–1682.
55. Devic E, Xiang Y, Gould D, Kobilka B. Beta-adrenergic receptor subtype-specific signaling in cardiac myocytes from beta(1) and beta(2) adrenoceptor knockout mice. Mol Pharmacol. 2001;60:577–583.
56. Delaey C, Van De Voorde J. Regulatory mechanisms in the retinal and choroidal circulation. Ophthalmic Res. 2000;32: 249–256.
57. Montero JA, Ruiz-Moreno JM, Sanchis-Merino E, Perez-Martin S. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab. Retina. 2013;33:508–512.
58. Wachtmeister L. Oscillatory potentials in the retina: what do they reveal. Prog Retin Eye Res. 1998;17:485–521.
59. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res. 2004; 23:91–147.
60. Hatzopoulos KM, Vessey KA, Wilkinson-Berka JL, Fletcher EL. The vasoneuronal effects of AT1 receptor blockade in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2014;55:3957–3970.
61. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1–29.
62. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–371.
63. Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res. 2008;27:622–647.
64. Kiba A, Sagara H, Hara T, Shibuya M. VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice. Biochem Biophys Res Commun. 2003;301:371–377.
65. Nagy JA, Senger DR. VEGF-A, cytoskeletal dynamics, and the pathological vascular phenotype. Exp Cell Res. 2006;312:538–548.
66. Mori A, Miwa T, Sakamoto K, Nakahara T, Ishii K. Pharmacological evidence for the presence of functional beta(3)- adrenoceptors in rat retinal blood vessels. Naunyn Schmiedebergs Arch Pharmacol. 2010;382:119–126.
67. Steinle JJ, Booz GW, Meininger CJ, Day JN, Granger HJ. Beta 3- adrenergic receptors regulate retinal endothelial cell migration and proliferation. J Biol Chem. 2003;278:20681–20686.
68. Steinle JJ, Zamora DO, Rosenbaum JT, Granger HJ. Beta 3- adrenergic receptors mediate choroidal endothelial cell invasion, proliferation, and cell elongation. Exp Eye Res. 2005;80:83–91.
69. Zhang SX, Sima J, Shao C, et al. Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes. Diabetologia. 2004;47:124–131.
70. Gu X, Samuel S, El-Shabrawey M, et al. Effects of sustained hyperoxia on revascularization in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2002;43:496–502.